Targeted therapy for nasopharyngeal cancer is generally used in the treatment of advanced stage patients, and it is usually not used alone, and most of them need to be used in combination with radiotherapy, chemotherapy and other treatments, which can enhance the anti-tumor effect to a certain extent and achieve better curative effect. Clinically, the treatment of nasopharyngeal cancer is mainly based on radiotherapy, and advanced patients can combine with chemotherapy or targeted therapy at the same time, and some patients can achieve good tumor shrinkage effect, or make the tumor condition of nasopharyngeal cancer stable and not developing. At present, targeted drugs for nasopharyngeal cancer mainly include monoclonal antibodies and tyrosine kinase inhibitors, monoclonal antibodies include cetuximab, bevacizumab, nitolizumab and so on, and there is also a class of tyrosine kinase inhibitors, such as gefitinib, erlotinib and so on, however, these drugs are still in the stage of clinical research for nasopharyngeal cancer treatment. Side effects such as skin rash, nausea, diarrhea, fever, drop in blood pressure, etc. may occur after the use of these drugs, which need to be used under the guidance of a professional doctor, and should not be used by oneself.